Sermorelin

Sermorelin (sermorelin acetate) is a synthetic 29-amino-acid peptide representing the first 29 residues of human growth hormone-releasing hormone (GHRH), also designated GRF (1-29) or GHRH (1-29). ^(1,2) Native GHRH is a 44-amino-acid peptide produced in the arcuate nucleus of the hypothalamus that travels to the anterior pituitary gland to stimulate growth hormone (GH) synthesis and secretion. Research established that only the first 29 amino acids are required for full biological activity, and sermorelin was synthesized (also spelled synthesized) as this minimally active fragment. ^(1,2)

Sermorelin has a distinguished regulatory history that sets it apart from most research peptides. It was FDA-approved on September 26, 1997, under NDA 20-443. EMD Serono marketed it under the brand name Geref for the treatment of idiopathic growth hormone deficiency (GHD) in children with growth failure. ^(2,3) A separate approval (NDA 19-863) covered the diagnostic formulation (Geref Diagnostic) for assessing pituitary GH secretory capacity in adults and children. ⁽³⁾ These approvals validated sermorelin’s mechanism of action, safety profile, and manufacturing standards through the full FDA New Drug Application process.

EMD Serono voluntarily discontinued Geref in 2008, citing commercial and manufacturing difficulties rather than safety or efficacy concerns. ⁽³⁾ The FDA formally confirmed this in a 2013 Federal Register determination, stating that “GEREF (Sermorelin Acetate) injection was not withdrawn from sale for reasons of safety or effectiveness.” ⁽³⁾ This formal determination means that any manufacturer can apply to produce generic sermorelin through an abbreviated new drug application (ANDA), and compounding pharmacies can legally prepare sermorelin under physician supervision. Sermorelin was notably not included in the FDA’s September 2023 Category 2 bulk drug substance restrictions that affected 19 other peptides. ⁽⁴⁾

Sermorelin is prohibited by the World Anti-Doping Agency (WADA) under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics, specifically S2.2: Growth Hormone Releasing Factors, where it is explicitly named alongside tesamorelin and CJC-1295. ⁽⁵⁾ The prohibition applies at all times, both in-competition and out-of-competition.

Healius supplies sermorelin as a lyophilized (also referred to as lyophilized) powder in 5mg and 10mg vials, intended strictly for laboratory and research applications.

Sermorelin’s mechanism of action differs fundamentally from that of exogenous recombinant human growth hormone (rhGH) injections, and this distinction is critical for understanding its research profile and safety profile. ^(1,2,6)

When administered, sermorelin binds to growth hormone-releasing hormone receptors (GHRHR) on somatotroph cells in the anterior pituitary gland. ^(1,2) This binding activates a stimulatory G-protein (Gs) signaling cascade that triggers two key responses: immediate release of stored GH from secretory granules and increased transcription of the GH gene (enhanced GH mRNA production), which builds the pituitary’s reserve capacity for future GH secretion. ^(1,2,6) This dual action, releasing existing GH stores while building production capacity, is unique to GHRH-pathway stimulation and is not replicated by direct GH injection.

Critically, sermorelin promotes pulsatile GH secretion that mirrors the body’s natural diurnal rhythm rather than producing the constant, supraphysiological levels associated with exogenous rhGH. ^(1,2) Natural GH release occurs in bursts, with the largest pulse occurring during deep slow-wave sleep. Sermorelin preserves this pulsatile pattern because its effects are regulated by somatostatin, the hypothalamic hormone that inhibits GH release. ^(1,2) When GH or IGF-1 levels rise to a threshold, somatostatin is released and suppresses further GH secretion regardless of sermorelin stimulation. This negative feedback loop makes sermorelin virtually impossible to overdose in the traditional sense: the pituitary stops responding when GH levels are adequate. ^(2,6)

This somatostatin regulation is the primary safety advantage of sermorelin (and all GHRH analogs) over exogenous rhGH. Direct GH injection bypasses the pituitary entirely, delivering the administered dose directly into the bloodstream, with no physiological brake. Sermorelin, by contrast, works through the body’s existing regulatory architecture, stimulating the pituitary to produce GH up to its maximum natural capacity but not beyond it. ^(2,6)

Once GH is released into the bloodstream, it travels to the liver and other tissues where it stimulates production of insulin-like growth factor 1 (IGF-1), the primary mediator of GH’s anabolic and metabolic effects. ⁽¹⁾ Sermorelin thus supports the entire GH/IGF-1 axis: hypothalamic signal (sermorelin as GHRH analog), pituitary response (GH release), and peripheral effect (IGF-1 production). By maintaining pituitary function and the integrity of this axis, sermorelin helps preserve the growth hormone neuroendocrine system, which is the first hormonal system to deteriorate with age. ^(2,6)

Sermorelin’s research profile centers on the downstream effects of restored GH/IGF-1 axis function, with published evidence spanning pediatric growth, adult body composition, sleep quality, and age-related hormonal decline. ^(1,2,6,7)

The foundational clinical evidence comes from the Geref approval studies in pediatric GHD, in which sermorelin was shown to be effective in stimulating linear growth. A 1996 study showed that daily sermorelin injections boosted growth rates in 74% of children within six months. ⁽²⁾ In adults, Corpas et al.  ⁽¹⁹⁹²⁾ published a landmark study in the Journal of Clinical Endocrinology and Metabolism demonstrating that GHRH (1-29) administered twice daily reversed the decreased GH and IGF-1 levels characteristic of aging (also spelled aging) in older men. ⁽⁷⁾ This study was among the first to demonstrate that the age-related decline in GH is due to reduced GHRH signaling rather than pituitary failure, meaning the pituitary retains the capacity to produce GH if adequately stimulated. ⁽⁷⁾

Body composition effects are the primary driver of adult interest in sermorelin. GH/IGF-1 axis activation promotes lean body mass preservation, fat metabolism (particularly visceral fat reduction), bone mineral density maintenance, and collagen synthesis. ^(1,6) These effects are especially relevant in the context of age-related somatopause, the progressive decline in GH secretion that begins in the third decade of life and accelerates after age 50, contributing to increased adiposity, decreased muscle mass, reduced bone density, and impaired recovery capacity. ⁽⁶⁾

Sleep quality represents an often-overlooked benefit of sermorelin research. The largest natural GH pulse occurs during Stage 3 NREM (slow-wave) sleep, and the relationship between GH and sleep is bidirectional: adequate GH supports deep sleep, and deep sleep promotes GH release. ⁽⁶⁾ By restoring pulsatile GH secretion, sermorelin may support the natural nocturnal GH surge and its associated sleep quality benefits. Many research protocols administer sermorelin before bedtime specifically to capitalize (also spelled capitalize) on this sleep-GH relationship.

Gender-specific research interest is reflected in the search data. For men, sermorelin is primarily researched for lean body mass, fat loss, recovery capacity, and age-related GH decline. ^(1,6) For women, research interest extends to skin quality and collagen synthesis (through GH-mediated IGF-1), body composition, and bone density maintenance during perimenopause and menopause when GH decline compounds the effects of estrogen loss. ⁽⁶⁾

Regarding the frequently searched “before and after” query: published clinical data from the Corpas et al. study demonstrated measurable increases in GH and IGF-1 levels in elderly men after GHRH (1-29) treatment. ⁽⁷⁾ Individual responses vary based on age, baseline pituitary reserve, and protocol parameters. Sermorelin is not expected to produce dramatic visual transformations in short timeframes; its effects on body composition and aging markers accumulate gradually over weeks to months of consistent use.

Sermorelin and Tesamorelin are both GHRH analogs that stimulate pituitary GH release through the same receptor (GHRHR), but they differ in structure, regulatory status, potency, and clinical evidence base. ^(1,2,8)

Structurally, sermorelin consists of the first 29 amino acids of native GHRH (GRF (1-29)), which represent the minimal fragment required for full biological activity. Tesamorelin consists of all 44 amino acids of native GHRH with a trans-3-hexenoic acid modification at the N-terminus that protects against enzymatic degradation, providing improved metabolic stability and a longer effective half-life. ⁽⁸⁾ In simple terms, tesamorelin is a stabilized full-length GHRH analog, while sermorelin is the minimally active fragment without stabilization modifications.

Regulatory status differs significantly. Sermorelin (Geref) was FDA-approved in 1997 for pediatric GHD and was voluntarily discontinued in 2008 for commercial reasons. ⁽³⁾ Tesamorelin (Egrifta) is currently FDA approved ⁽²⁰¹⁰⁾ for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, supported by Phase III data in 806 patients showing 15-18% visceral fat reduction by CT imaging. ⁽⁸⁾ Tesamorelin has the stronger current regulatory standing with active FDA approval.

Clinical evidence also diverges. Tesamorelin has large-scale Phase III efficacy data specifically demonstrating visceral fat reduction. ⁽⁸⁾ Sermorelin’s clinical evidence base is primarily pediatric (also spelled pediatric) GHD and the Corpas et al. adult GH restoration study. ^(2,7) For researchers specifically investigating visceral adipose tissue, tesamorelin has the more directly relevant evidence base. For researchers investigating general GH axis restoration, pituitary reserve assessment, or age-related GH decline, sermorelin has the longer historical research record and more accessible compounding availability.

Both compounds are explicitly named on the WADA Prohibited List under S2.2. ⁽⁵⁾ Both are GHRH analogs that work through physiological GH stimulation rather than direct GH replacement. In research contexts, they are often considered within the same category but with different strengths: sermorelin for accessibility and long-term safety record, tesamorelin for clinical potency and visceral fat data.

1. Wikipedia. Sermorelin. GRF (1-29), first 29 amino acids of GHRH, GHRHR binding, somatostatin regulation, pulsatile GH release. Updated January 2026.

2. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PubMed: 18031173.

3. Federal Register. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn from Sale for Reasons of Safety or Effectiveness. March 4, 2013. NDA 20-443 (approved Sept 26, 1997), NDA 19-863. Discontinued Dec 2008 by EMD Serono.

4. FDA Interim Policy on Compounding Under Section 503A. Sermorelin is not included in the September 2023 Category 2 bulk drug substance restrictions.

5. WADA Prohibited List 2026—section S2.2: Growth Hormone Releasing Factors. Sermorelin is explicitly named alongside tesamorelin and CJC-1295.

6. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308. PMC2699646.

7. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in older men. Journal of Clinical Endocrinology and Metabolism. 1992;75(2):530-535.

8. Tesamorelin (Egrifta): FDA-approved in 2010 for HIV lipodystrophy. Full-length 44-amino-acid GHRH analog with trans-3-hexenoic acid modification. Phase III: 806 patients, 15-18% VAT reduction.

9. Ipamorelin: selective growth hormone secretagogue (GHS) acting through ghrelin/GHS receptor (GHSR/GHS-R1a). Minimal cortisol, prolactin, and ACTH effects. Complementary to GHRH-pathway stimulation.

10. CJC-1295 no DAC (Mod GRF 1-29): modified sermorelin with 4 amino acid substitutions at positions 2, 8, 15, 27 for DPP-IV resistance. Same GHRH receptor target, improved metabolic stability.

11. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2): S149-S159.

12. Al Musaimi M, et al. Exploring FDA-approved frontiers: Insights into natural and engineered peptide analogs in the GLP-1, GIP, GHRH, CCK, ACTH, and alpha-MSH realms. 2024. PMC10968328.

13. Innerbody. Sermorelin Peptide: Benefits, Safety, and Buying Advice. January 2026. Comparison of sermorelin vs tesamorelin structural and regulatory differences.

14. Eden Health. Is Sermorelin Safe? FDA, Risks, and Side Effects. November 2025. Historical FDA timeline, compounding status, and side effect profile.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.